Anti-Platelet Agents Market
Anti-Platelet Agents Market Analysis By Drug Type (Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Application (Angioplasty, Percutaneous Coronary Interventions, Others), By End User & Region – Global Market Insights 2023 to 2033
Analysis of Anti-Platelet Agents Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Anti-Platelet Agents Market Outlook (2023 to 2033)
The global anti-platelet agents market is valued at US$ 2.4 billion in 2023 and is forecasted to expand at a CAGR of 7% during the study period of 2023 to 2033. As such, global demand for anti-platelet agents is projected to reach a market valuation of US$ 4.8 billion by the end of 2033.
Anti-platelet medications or agents are incorrectly referred to as ‘blood thinners’. They are used at a significant rate for the prevention of blood clots. They work by preventing some hazardous clots from sticking together.
As per this detailed study conducted on the global market, anti-platelet medications have been used to provide treatment to patients who are undergoing some difficult surgical operations, for instance, angioplasty. In addition, fast-changing lifestyles are leading to the rising prevalence of cardiovascular diseases.
- The World Health Organization (WHO) has provided some estimations. According to that around 15 million people around the world die every year from heart conditions, for example, heart strokes.
Rising cardiovascular issues are further estimated to fuel demand for anti-platelet agents to ensure effective healthcare solutions for people. These anti-platelet agents prevent clotting by restricting the activity of the platelet to bind or stick together. Furthermore, clotting of blood is generally a physiological reaction of the human body that assists in controlling any sort of external bleeding at the time of injury.
Blood clotting within blood vessels can cause some serious complications as they restrict the flow of blood. As a result, different anti-platelet medications are prescribed as therapeutic solutions to stop blood clotting as feasible and quick solutions.
Rising aging population is also one of the pivotal factors that generate lucrative opportunities owing to their weaker immune system, which can cause serious health issues. In addition, due to their age, these people are prone to various heart issues and thus contributing to increased demand for anti-platelet agents.
The proliferation of anticoagulant or antithrombotic drugs can aid in the rising demand for anti-platelet agents during the forecast period. Surging thrombotic events are also predicted to fuel demand for anti-platelet agents in the coming years. In recent years, various technological advancements are taking place around the world intending to improve the efficiencies of anti-platelet agents and can help industry players to acquire substantial revenue in the forecasted period.
Anti-Platelet Agents Market Size in 2023
US$ 2.4 Billion
Projected Market Value (2033)
US$ 4.8 Billion
Estimated Market Growth Rate (2023 to 2033)
Canada Market Growth Rate (2023 to 2033)
Germany Market Growth Rate (2023 to 2033)
Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is Demand for Anti-Platelet Agents Increasing at a Fast Pace?
“Rising Worldwide Prevalence of Cardiovascular Diseases”
Growing cases of cardiovascular diseases are propelling demand for anti-platelet agents. Not only in developing but also in developed economies, cardiovascular disorders are one of the leading causes of death.
- More than 800,000 people in the United States every year die due to stroke and some other cardiovascular disorders, as per the information provided by the Centers for Disease Control and Prevention (CDC).
- In the year 2020, around 3,658 heart transplantation procedures had been performed in the United States. Some of the noticeable incidences of heart transplantations include the states of California (496), Texas (302), Florida (288), and New York (250).
“Increasing Investments in Healthcare Infrastructure Development”
Countries around the world are investing at an increased rate in healthcare, which further helps to improve respective facilities. In addition, public as well as private organizations, across the globe are taking initiatives to spread awareness about myriad fungal infections that can be treated with the use of anti-platelet agents.
A sedentary lifestyle of individuals can result in increased health disorders. Moreover, the rising population of geriatric people can also propel the demand for anti-platelet agents owing to their cardiovascular issues. The increasing thrombotic events will also fuel demand for anti-platelet agents in the coming years.
“Increasing Number of Research & Development Activities”
Key manufacturers of anti-platelet agents are involved in various research & development activities that can further generate beneficial opportunities for them.
For instance :
- PhasBio Pharmaceuticals, Inc. is a biopharmaceutical company. In April 2022, it announced the comprehensive results from its Phase 2b clinical trial of bentracimab. It was presented on April 2, 2022, at the 71st Annual Scientific Session at the American College of Cardiology during a Late Breaking Featured Clinical Research Presentation.
Bentracimab is designed for the reversal of the antiplatelet activity of ticagrelor among patients who need surgery or experiencing uncontrolled bleeding.
How Can Sales of Anti-Platelet Agents Be Adversely Affected?
“Side Effects and Comparatively High Cost of Anti-Platelet Agents”
The cost of anti-platelet agents is comparatively higher. Thus, the easy availability of these agents for everyone becomes a bit difficult. In addition, there are a few side effects that are related to the consumption of anti-platelet agents and can put adverse impacts on their demand.
“Lack of Healthcare Facilities in Developing Economies”
Developing economies around the world are not well-equipped with advanced healthcare infrastructure or facilities. There is a lack of advanced and well-established healthcare facilities there. In addition, limitations in the safety and efficacy of some anti-platelet drugs can also challenge their demand.
Which Region is Estimated to Emerge as a Lucrative Market for Anti-Platelet Agent Suppliers?
“Adoption of Advanced Healthcare Technologies in North America”
North America holds a dominating position in the global market owing to the rising adoption of new and advanced healthcare technologies. Furthermore, the growing demand for disease-specific treatment is also predicted to generate revenue.
North America is considered the hub of prominent suppliers who are penetrating the region at a significant rate. They are investing at a significant rate in various R&D activities and in clinical trials that are related to anti-platelet agents.
A significant number of patients in North America are suffering from ischaemic strokes and myocardial infarction that require anti-platelet agents for their treatment.
For instance :
- Around 800,000 people in the United States suffer from stroke each year. Among these, around 87% are ischaemic strokes.
Asia Pacific is also projected to experience substantial growth in the coming years due to the growing investments by players in different R&D activities. Further, rising government initiatives to minimize the count of deaths, which are caused by thrombotic cardiovascular disease are also contributing to product demand.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What is the Stance of Japan for Anti-Platelet Agents?
“Increased Investments in R&D Activities”
Sales of anti-platelet agents in Japan are expected to expand at a moderate CAGR of 3.7% through 2033. The government of Japan is spending at a significant rate on R&D activities. These research activities will help Japan to reduce the number of deaths that are caused due to thrombotic cardiovascular disease.
How Can Anti-Platelet Agents Manufacturers Benefit in the United States?
“Growing Cases of Ischaemic Strokes and Myocardial Infarction”
In recent years, there is a significant increase in the count of people who are suffering from ischaemic strokes as well as myocardial infarction. Thus, there arises a crucial requirement for anti-platelet agents. In addition, some of the prominent players, which are operating in the United States can also help the country to gain traction in the regional market.
Demand for anti-platelet agents in the United States was more than US$ 550 million in 2022-end. Moreover, Sales of anti-platelet agents in Canada are predicted to advance at a high CAGR of 6.2% during the forecast period from 2023 to 2033.
Why is There Increasing Demand for Anti-Platelet Agents in Germany?
“Rapid Development of Healthcare Infrastructure”
The value of anti-platelet agents in Germany is anticipated to progress at a steady CAGR of 4.4% from 2023 to 2033. The healthcare infrastructure of Germany has been undergoing significant development in recent years. In addition, rising government initiatives to increase awareness about myocardial infarction are further contributing to increased demand for anti-platelet agents.
Which Distribution Channel is Estimated to Lead Revenue Generation?
“Retail Pharmacies to Generate Substantial Revenue for Market Players”
Key segments based on distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others are analyzed in the recently published research report by Fact.MR, a provider of market research and competitive intelligence. Considering the post-pandemic scenarios, the retail pharmacies segment is estimated to expand at a revised CAGR of 7.1% during the forecast period from 2023 to 2033.
Further, the hospital pharmacies segment is estimated to progress at a CAGR of 7% through 2033 while reaching a valuation of US$ 1.7 billion by the end of 2033.
Industry players are investing at a significant rate in new developments. These players are concentrating to strengthen the supply chain management system and providing quality products to end users. In the respective manufacturing process, they adhere to imposed rules and regulations that are set for quality control of end products and causing minimal environmental impacts.
These players are adopting numerous strategies, including merger & acquisition, approvals, partnerships, and others to generate untapped opportunities.
For instance :
- Alfasigma in June 2021 announced that it has received approval for the European license, which was for bentracimab from PhaseBio. Further, Bentracimab is a new human monoclonal antibody fragment. It has been designed for the reversal of the anti-platelet effects of Brilique/Brillinta in clinical tests.
Key suppliers of anti-platelet agents are Aspen, The Medicines Company, Sanofi, Pfizer, Johnson & Johnson, Daiichi Sankyo, Bristol-Myers Squibb, and Otsuka.
Segmentation of Anti-Platelet Agents Industry Research
By Drug :
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Application :
- Percutaneous Coronary Interventions
- Myocardial Infraction
- Dental Surgeries
- Arterial Thrombosis
By End User :
- Ambulatory Surgical Centers
- Emergency Service Centers
By Region :
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- FAQs -
In 2023, the market for anti-platelet agents is valued at US$ 2.4 billion.
The global anti-platelet agents market is forecasted to expand at a CAGR of 7% during the forecast period of 2023 to 2033.
Sales of anti-platelet agents in Canada are anticipated to increase at a CAGR of 6.2% from 2023 to 2033.
The anti-platelet agents market is expected to reach a valuation of US$ 4.8 billion by 2033-end.
Demand for anti-platelet agents in Germany is predicted to advance at a CAGR of 4.4%.
Prominent manufacturers of anti-platelet agents are Aspen, The Medicines Company, Sanofi, Pfizer, Johnson & Johnson, Daiichi Sankyo, Bristol-Myers Squibb, and Otsuka.